Exhibit 10.15
Lonza
AMENDMENT NO. 2
TO
THE DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT
DATED 08 JANUARY 2004
BETWEEN
LONZA BIOLOGICS ***
AND
TRUBION PHARMACEUTICALS INC.
Re:
Schedule 2 - Services
Updated Stages
Stage 1 ***
Stage 2 ***
Stage 8 ***
Schedule 2 - Services
New Stages
Add Stage 16 ***
Add Stage 17 ***
Add Stage 18 ***
Schedule 3 - Price and Payment
Updated Price and Payment Terms for Updated Stages and New Stages
Lonza
THIS AMENDMENT is made the 20 day July 2004
BETWEEN
1. LONZA BIOLOGICS ***, the registered office of which is at *** ("LB") and
2. TRUBION PHARMACEUTICALS, INC., of ▇▇▇▇ ▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇
▇▇▇▇▇, ▇▇▇ (herein after referred to as the "Customer").
WHEREAS
A. Customer and LB entered into a development and manufacturing services
agreement dated 08 January 2004 ("the Agreement"), under which LB is
required to perform Services relating to the Cell Line and the Product, as
further described in the Agreement, and
B. Customer would like LB to perform additional services under the Agreement,
and
C. LB is prepared to perform the additional services, and the parties wish to
amend the Agreement accordingly and to make other revisions to the
Agreement.
NOW THEREFORE it is agreed as follows:
1. Amendments to Schedule 2, Stages 1, 2 and 8. Schedule 2 of the Agreement
shall be amended to revise Stage 1 ***, Stage 2 *** and Stage 8 (Production of
*** of cGMP Product at *** Scale), as follows:
1.1 Stage 1 of Schedule 2 shall now read In its entirety as follows:
STAGE 1 ***
1.1 OBJECTIVES
***
1.2 ACTIVITIES
***
1.3 DELIVERABLES
1.3.1 A report of activities for the shake flask and lab scale
fermenter activities.
1.3.2 A report of activities performed during virus testing of
the ***.
1.4 TIMESCALE
This stage may start upon creation of the *** Cell Line and receipt of the
*** Cell Line from the Customer. This stage shall be complete upon issue of the
report for the virus testing activities.
It is estimated that this stage shall be complete *** from commencement.
1.2 Stage 2 of Schedule 2 shall now read In its entirety as follows:
STAGE 2 ***
2.1 OBJECTIVES
***
2.2 ACTIVITIES
***
2.3 DELIVERABLES
2.3.1 A report of activities carried out under this Stage 2 as
detailed in activity 2.2.6.
2.3.2 A one (1) page summary report to the customer for each
ampoule revival during the *** (activity 2.2.5).
2.4 TIMESCALE
Stage 2 may commence as soon as the selected PSS is available from Stage 1
of the Services.
Stage 2 shall be complete with the issue of the report (activity 2.3.1) and
it is estimated that this report will be issued *** from the commencement of
Stage 2.
It is estimated that the *** will be established *** from the commencement
of Stage 2.
-2-
1.3 Stage 8 of Schedule 2 shall now read in its entirety as follows:
STAGE 8 ***
8.1 OBJECTIVES
***
8.2 ACTIVITIES
***
8.3 DELIVERABLES
***
8.4 TIMESCALE
When the Customer and LB agree to the commencement of this Stage, this
stage may commence as soon as the *** is available for use and the Process
development activities and cGMP documents are complete.
This stage shall be complete upon issue of the certificate of analysis for
the Batch of Product.
It is estimated that Product will be delivered *** from commencement of the
Stage. If Customer requests in writing, the Product can be shipped in quarantine
prior to release. It is estimated that this shipment could occur *** from
commencement of the Stage.
-3-
2. Amendments to Schedule 2, Stages 16, 17, and 18. Schedule 2 of the
Agreement shall be amended to include the following additional stages, Stage 16
*** Testing for Adventitious Agents, Stage 17 (Cell Culture (***) Evaluation and
Stage 18 (Cell Culture *** Evaluation):
2.1 A new Stage 16 shall be added to Schedule 2 of the Agreement and
shall read in its entirety as follows:
STAGE 16 ***
16.1 OBJECTIVES
16.1.1 To carry out additional testing on the *** as instructed
by the Customer.
16.2 ACTIVITIES
***
16.3 DELIVERABLES
16.3.1 Issue a copy of the Testing Laboratory reports including
description of materials and methods to the Customer containing the results
of the tests carried out in 16.2.1.
16.4 TIMESCALE
This Stage may commence as soon as the *** is available from Stage 2 and
upon signature of this Amendment 2. This Stage shall be complete upon issue of
the Testing Laboratory reports (activity 16.2.1) and it is estimated that these
reports shall be issued *** from commencement of this Stage.
-4-
2.2 A new Stage 17 shall be added to Schedule 2 of the Agreement and shall
read in its entirety as follows:
STAGE 17 ***
17.1 OBJECTIVES
***
17.2 ACTIVITIES
***
17.3 DELIVERABLES
17.3.1 A report of activities carried out under this Stage 17 as
detailed in activity 17.2.1,***.
17.4 TIMESCALE
Stage 17 may commence as soon as the *** is available from Stage 1 of the
Services.
Stage 17 shall be complete with the issue of the report of activities and
it is estimated that this report will be issued *** from the commencement of
Stage 17.
-5-
2.3 A new Stage 18 shall be added to Schedule 2 of the Agreement and shall
read in its entirety as follows:
STAGE 18 ***
18.1 OBJECTIVES
***
18.2 ACTIVITIES
***
18.3 DELIVERABLES
18.3.1 A report of activities carried out under this Stage 18.
18.4 TIMESCALE
Stage 18 may commence as soon as the *** is available from Stage 2 of the
Services.
Stage 18 shall be complete with the issue of the report of activities and
it is estimated that this report will be issued *** from the commencement of
Stage 18.
-6-
3. Amendments to Schedule 3. Schedule 3 of the Agreement shall be amended
to revise the price and terms of payment for Stages 1, 2 and 8, and to set forth
the price and payment terms for the additional Stages contained in this
Amendment No. 2, as follows:
SCHEDULE 3
Price and Terms of Payment
1. Price
In consideration for LB carrying out the updated Services described in
▇▇▇▇▇ ▇, ▇▇▇▇▇ ▇ and Stage 8; and the new Services as described in ▇▇▇▇▇ ▇▇,
▇▇▇▇▇ 17 and Stage 18, all as detailed in Schedule 2 as amended by this
Amendment No. 2, the Customer shall pay LB as set forth below, and Schedule 3 of
the Agreement shall be amended accordingly:
STAGE PRICE (***)
----- ----- -----
Stage 1 *** Price remains at ***
Stage 2 *** Price remains at ***
Stage 8 *** ***
Stage 16 *** Testing Laboratory charges actually incurred by LB plus ***
administration charge, with total cost (charges plus ▇▇▇▇-up)
estimated to be***.
Stage 17 *** ***
Stage 18 *** ***
2. Payment
Payment by the Customer of the Price for each Stage shall be made against
LB's invoices as follows:
2.1 For Stage 1
*** upon completion of Stage 1.
2.2 For Stage 2
*** upon completion of Stage 2.
2.3 For Stage 8
*** upon removal of an ampoule of *** out of freeze.
*** upon issue of a Certificate of Analysis.
2.4 For Stage 16
Testing Laboratory charges actually incurred by LB plus *** administration
charge, with *** payable upon completion of Stage 16.
2.5 For Stage 17
No charge to the Customer
-7-
2.6 For Stage 18
No charge to the Customer
4. Amendment to Clause 3.3 of the Agreement. In the first line of Clause 3.3 of
the Agreement, the words "The parties agree that the *** Batches of Product
manufactured under Stage 8..." shall be replaced by "The parties agree that the
Batch of Product manufactured under Stage 8...", and any subsequent references
to 'Batches' in Clause 3.3 shall be changed to 'Batch'.
5. Approval to Use of ***. In accordance with Clause 3.8 of the Agreement, the
Customer hereby gives its written approval to the use of *** as a Testing
Laboratory.
6. Defined Terms. Any capitalized term used but not defined in this Amendment
No. 2 shall have the meaning given in the Agreement.
7. Full Force and Effect. Save as herein provided all other terms and conditions
of the Agreement shall remain in full force and effect.
IN WITNESS WHEREOF the parties have caused this Amendment No 2 to be
executed by their duly authorised representatives thereunto as of the day and
year first above written.
Signed for and on behalf of
LONZA BIOLOGICS *** ***
----------------------------------------
***
----------------------------------------
Title
Signed for and on behalf of
TRUBION PHARMACEUTICALS, INC. /s/ ▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
----------------------------------------
President & CEO
Title
-8-
